 |
Dr. Borst-Eilers served as Minister of Health, Welfare and Sport of the Government of the Netherlands from August 1994 through July 2002, and as Deputy Prime Minister from 1998. Dr. Borst-Eilers graduated in medicine from the University of Amsterdam, trained in paediatrics and immunohaematology, and also earned a doctorate in medicine. She taught immunohaematology at Utrecht University, directed the blood bank at its University Hospital, and was medical director there from 1976-86. From 1986 to 1994 Dr. Borst-Eilers was vice-chairman of the Health Council. From 1991 through 1994 she was also Professor of Evaluation of Clinical Practice at the University of Amsterdam. She has served as a member or chair of a number of other groups, including: the Blood Transfusion Board; the Medical Research Ethics Core Commission; the Advisory Council for Science and Technology; and the Remmelink Commission on euthanasia. In 1997 she was appointed as a Fellow of the Royal College of Physicians in Edinburgh, and remains a foreign associate of the Institute of Medicine in Washington. She has been on the editorial boards of a number of medical journals and has published more than 60 articles on a range of topics including immunology, immunohaematology and medical ethics.
 |
Dr. Coutinho is executive director of the Infectious Disease Institute at Makerere University in Kampala, Uganda. From 2001 to 2007, he served as executive director of The AIDS Support Organization of Uganda (TASO), the largest AIDS care and support organization in sub-Saharan Africa. Prior to joining TASO, he worked in a range of capacities for the Royal Swaziland Sugar Corporation (RSSC) with progressively greater responsibility for community services, focusing especially on HIV. He established services including holistic prevention and care, voluntary counseling and testing, management of opportunistic infections, a TB clinic, an AIDS clinic, a peer education program as well as hospital management and palliative care for terminal AIDS patients. These services were implemented using a multi-sectoral approach that involved schools, communities, churches and unions in an expanded HIV prevention and care program. He has provided counseling and care to hundreds of AIDS patients in Uganda and Swaziland. Dr. Coutinho was a member of the interim board of the Global Fund to Fight AIDS, TB, and Malaria as the fund was established, and he also served as the vice chair of the Global Fund Technical Review Panel for two years. He has also been the vice chair of the board of the Regional AIDS Training Network (RATN), a member of the strategic advisory group for the WHO HIV/AIDS global strategy and currently a member of the scientific committee of the Academic Alliance for HIV/AIDS as well as a board member of the AIDS Information Center – the largest VCT NGO in Africa. He has published a number of articles on AIDS service provision. He holds an MBChB and an MSc from Makerere University and an MPH from the University of Witwatersrand.
 |
Dr. Peter Corr is a general partner with Celtic Therapeutics Management LLLP, a new product development group. Dr. Corr served as Senior Vice President for Science and Technology at Pfizer Inc from 2002 to 2006, when he retired. Prior to that Dr. Corr served as Executive Vice President, Pfizer Global Research & Development; and President, Worldwide Development. Before joining Pfizer in 2000, he was President of Pharmaceutical Research and Development at Warner Lambert/Parke Davis until the merger with Pfizer. Earlier, he served as Senior Vice President, Discovery Research, at Monsanto/Searle. Dr. Corr received his doctorate from Georgetown University School of Medicine and Dentistry and spent 18 years as a leading researcher in molecular biology and pharmacology at Washington University in St. Louis and was Professor, Department of Medicine (Cardiology) and Professor, Department of Pharmacology and Molecular Biology. His research has been published in more than 160 scientific manuscripts. He has also served on or is serving on the editorial board of several journals, including American Journal of Physiology, Circulation, Circulation Research, Molecular and Cellular Biochemistry, and the Journal of Cardiovascular Electrophysiology. Dr. Corr is a member of the Board of Governors of the New York Academy of Sciences and the Board of Regents of Georgetown University.
 |
Mr. Gupta is the senior partner worldwide of McKinsey & Company Inc. and was elected in April 2007 to serve as chair of the Global Fund. He joined the New York Office of McKinsey in 1973, assumed leadership of its Scandinavian offices in 1981 and joined the Chicago office in 1987. He assumed the role of Chicago office manager in 1989. Mr. Gupta served as the managing director worldwide of McKinsey from 1994 to 2003. Since joining the firm, Mr. Gupta has directed a number of projects aimed at helping companies develop new product/market strategies and reorganize for improved effectiveness and operations capabilities. He has a broad range of consulting experience with a variety of industries, including telecommunications, energy and consumer goods. Mr. Gupta maintains many educational, professional and business affiliations. He is chairman of the Board of Associates of the Harvard Business School, chairman of the India AIDS Initiative of The Gates Foundation, a member of the board of the Global Fund for AIDS, Tuberculosis and Malaria, a member of the board of the Global Health Council, a member of the World Economic Forum Foundation Board, and a member of the United Nations Commission on the Private Sector and Development. Mr. Gupta holds a Bachelor of Technology in mechanical engineering from the Indian Institute of Technology and an M.B.A. from Harvard Business School.
 |
Dr. Harrison has invested in life sciences since 1991. Currently he is the managing general partner of Apple Tree Partners, a life sciences venture capital firm. Prior to founding Apple Tree, Dr. Harrison was a general partner at Oak Investment Partners and earlier had been a venture partner at Sevin Rosen Funds. His exited investments include: ArQule, Coelacanth, Cyrano Sciences, HeartWare Limited (Australia), Informed Access, Ultracision and ViroPharma. Current portfolio investments include Structural GenomiX and GeneOS Oy. Dr. Harrison serves as founding investor, acting CEO and chairman of numerous portfolio companies. He received an AB from Princeton University, an MD and MBA both from Columbia University and completed a surgery internship at the Presbyterian Hospital. Dr. Harrison is Chairman of the Board of Trustees of the New York Studio School for Drawing, Painting and Sculpture.
 |
Dr. Kessler is professor of pediatrics at the University of California, San Francisco School of Medicine, where he had also served as dean. He was formerly the dean of the Yale University School of Medicine. Dr. Kessler was commissioner of the U. S. Food and Drug Administration (FDA) from November 1990 until March 1997, appointed first by President George H.W. Bush and reappointed by President Clinton. Dr. Kessler has a wide range of experience in research, clinical medicine, education, administration and the law. He is a 1973 magna cum laude, Phi Beta Kappa graduate of Amherst College. He received his J.D. degree in 1978 from The University of Chicago Law School, where he was a member of the Law Review, and his M.D. degree from Harvard Medical School in 1979. He did his internship and residency in pediatrics at the Johns Hopkins Hospital. In 1986, he earned an advanced professional certificate from the New York University Graduate School of Business Administration. From 1984 until his FDA appointment, he was the medical director of the Hospital of the Albert Einstein College of Medicine in the Bronx, New York, where he held teaching appointments in the Pediatrics and Epidemiology and Social Medicine departments. From 1986 until 1990, Dr. Kessler also taught food and drug law at the Columbia University School of Law in New York. He was a consultant to the U.S. Senate Labor and Human Resources Committee from 1981 until 1984.
Ms. Totsie Memela-Khambule is the managing director of Post Bank, which is part of the South African Post Office. She is responsible for leading the state-owned institution to become a bank of choice for underserved communities in urban and rural South Africa. She is also a director in Memela Pratt Associates (MPA), a woman-owned executive search firm. Prior to joining Post Bank, she was CEO of customer services and retention for First National Bank’s home loans division. In 2000, she was appointed acting managing director at the Land Bank, where she was previously General Manager of Operations. Ms. Memela-Khambule also served as regional manager for People's Bank, where she was responsible for managing 25 branches in three provinces. In 1993, Ms. Memela-Khambule joined Nedcor as its community liaison manager and became branch manager in 1994. Prior to entering banking and finance, Ms. Memela-Khambule served in the office of the former secretary general of the African National Congress (ANC), Cyril Ramaposa, who was part of the team responsible for drafting the South African constitution. She began her career with the ANC in 1978 in Swaziland, Botswana and Zimbabwe. Ms. Memela-Khambule is currently a member of the board of directors of the Rural Housing Loan Fund, Teba Bank Limited and Lekana, a division of First Rand. She holds a Bachelor of Arts in social science from the University of Swaziland and a Master of Public Administration from the University of Zimbabwe.
 |
Ms. Nayyar is PATH's country program leader in India. Before joining PATH, she worked with the International AIDS Vaccine Initiative (IAVI), where she was India country director and then vice president for country and regional programs, working both in New Delhi and in New York at the organization's headquarters. She has a master's degree in population studies and underwent training at the Johns Hopkins University on health communications. She began her career developing educational tools for kindergarten children and then joined the national magazine ‘Parenting’ as assistant editor. Equipped with editorial and media relations experience, she was responsible for communications and advocacy activities for the South and East Asia Region at the Population Council for six years from 1996 to 2002. During this period, she planned and co-coordinated several advocacy and communications projects on reproductive and sexual health issues. She also conducted numerous training programmes for researchers, government agencies and NGOs on reproductive and sexual health communication. She developed many publications on emergency contraception, expanded and informed contraceptive choice, and reproductive tract infections (RTIs) and sexually transmitted infections (STIs) for the Population Council and for partner agencies such as United Nations Population Fund. Some of these publications on emergency contraception and RTIs and STIs were subsequently mass-produced by the government of India for programme managers.
 |
Dr. Profy is currently the Vice President of Preclinical Development at Indevus Pharmaceuticals (formerly Interneuron), where he manages the development program for PRO 2000, a candidate microbicide in large-scale efficacy trials as well as non-clinical studies for other Indevus programs. Dr. Profy has extensive experience in microbicide development, has managed the drug discovery and development process at Procept Inc., and has been actively involved in drug research, as both a principal investigator and research scientist. Prior to his work with Procept Inc., Dr. Profy held key scientific research positions at Repligen Corporation in Cambridge, MA. Dr. Profy received his Ph.D. in Bio-organic Chemistry from Cornell University, and has published widely on microbicide development and HIV prevention.
 |
Dr. Rosenberg is the Chief Executive Officer of IPM, responsible for providing vision, leadership and direction to the organization. Previously, Dr. Rosenberg was the Scientific Director for the HIV Prevention Trials Network (HPTN) at Family Health International from 1999 to 2002. In that role, she assured scientific and operational coordination for clinical trials in the areas of prevention of mother-to-child, sexual and intravenous drug use transmission of HIV both domestically and internationally. From 1987-1999, Dr. Rosenberg worked in several capacities at the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH). In her role as Senior Scientist at the Division of AIDS, she was responsible for HIV-prevention clinical trials in adult populations. As Assistant Director for Prevention Research, she coordinated prevention activities in the areas of HIV infection and other sexually transmitted diseases as well as tuberculosis, representing NIH on the Public Health Service Task Force to Combat Multi-Drug Resistant TB and co-chairing the TB Research Subcommittee. Dr. Rosenberg received her undergraduate degree (A.B.) in biology and mathematics from Douglass College, Rutgers University; a master’s degree (S.M.) in epidemiology and a doctoral degree (Sc.D.) in microbiology from the Harvard School of Public Health.
 |
Dr. Rossert-Blavier served as the director general of AIDES in France from 1997 to 2007. In that role, she fostered the development of AIDES' international programs in sub-Saharan Africa and in the enlarging Europe. Since its founding in 1984, AIDES has taken a comprehensive approach to address HIV/AIDS and people living with HIV/AIDS through programs that include prevention, harm reduction policies, testing and care. AIDES currently works through its 76 chapters in France, and a network of 16 NGOs in eight Francophone African countries. AIDES’ intervention focuses on a community-based involvement. Previously, Dr. Rossert-Blavier was the HIV/AIDS program manager for the International Center of Childhood and Family in Paris and from 1989 through 1992 served as the general representative and supervisor of the prevention program of the AIDES Fédération Nationale, a consortium of NGOs fighting AIDS in France. Dr. Rossert-Blavier received her M.D. at Rouen University in France, and her Master of Public Health from the University of Texas in the United States. She has authored a number of publications for people living with HIV and articles in the main French newspapers regarding political issues on the international HIV/AIDS fight. In 2003 she was appointed for a two-year term on the board of directors of the Global Fund to Fight AIDS, Tuberculosis, and Malaria (GFATM) to represent developed-country NGOs. In March 2004, she was unanimously elected vice chair of the GFATM, the first woman and first member of civil society to access such a high level position in the GFATM. Dr. Rossert-Blavier’s areas of expertise include community health, HIV/AIDS, developing countries and political advocacy.
 |
Ms. Yuvaraj is Program Manager for HIV and Sexual Reproductive Health at PATH’s India office, where she manages a project to support the activities of the National Working Group on Microbicides and is the technical advisor on all issues related to the organization’s work with HIV-positive people in India. Diagnosed as HIV-positive in 1997, she has played a vital role in broadening political and social responses to the epidemic in India. Ms. Yuvaraj began her work by establishing a local organization to support others living with HIV in her community, which continues to be a strong and effective program. Through her participation in various forums that address the involvement of people living with HIV/AIDS, she has been instrumental in mobilizing communities affected by HIV/AIDS to raise their voices, needs and concerns to build supportive environments. During her tenure with the Global Fund to Fight AIDS, Tuberculosis and Malaria as the board representative of the communities’ delegation, she strengthened the delegation’s participation by systematizing a selection and induction process, formalizing communication and monitoring the effectiveness of its members. Currently, Ms. Yuvaraj provides technical support to the India Campaign for Microbicides and the Indian National AIDS Control Organization on the Greater Involvement of People Living with and Directly Affected by HIV/AIDS. She is also a member of the national advisory board of the Indian chapter of the International AIDS Vaccine Initiative and the Indian Council of Medical Research. Additionally, she is a steering committee member, advising the development of national strategies for phase III of the National AIDS Control Programme in India. Ms. Yuvaraj is also an active member of the International Community of Women Living with HIV/AIDS and several other international groups.
|
